摘要:
A method for treating core binding factor (CBF) leukemia in a subject, comprising administering to a subject having CBF leukemia a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or ester thereof, that inhibits CBFβ and RUNX1 binding in the subject, thereby treating the CBF leukemia.
摘要:
Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.
摘要:
Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.
摘要:
Disclosed are compounds of formulas (I) and (III) for treating or preventing a disease or disorder responsive to activation of a D1 dopamine receptor agonist in a mammal in need thereof, wherein m, n, R1-R6, and R11-R13 are as defined herein. Examples of such disease or disorder include Alzheimer's Disease, schizophrenia, Parkinson's disease, a dyskinesia, and Huntington's disease.
摘要:
A method for treating core binding factor (CBF) leukemia in a subject, comprising administering to a subject having CBF leukemia a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or ester thereof, that inhibits CBFβ and RUNX1 binding in the subject, thereby treating the CBF leukemia.